Texas HB3057 expands access to Chimeric Antigen Receptor T-Cell (CAR T) therapy by allowing the cancer treatment to be provided in any certified.

Texas HB3057 amends the Insurance Code to create a new chapter on network standards for CAR T therapy. The bill aims to expand access to this cancer treatment by allowing it to be provided in any certified healthcare facility, as defined by the Food and Drug Administration. This applies to various types of health benefit plans, including small employer health benefit plans, standard health benefit plans, and basic coverage plans. The provisions take effect on January 1, 2026.

Texas HB3057 expands access to Chimeric Antigen Receptor T-Cell (CAR T) therapy by allowing the cancer treatment to be provided in any certified.

Texas HB3057 amends the Insurance Code to create a new chapter on network standards for CAR T therapy. The bill aims to expand access to this cancer treatment by allowing it to be provided in any certified healthcare facility, as defined by the Food and Drug Administration. This applies to various types of health benefit plans, including small employer health benefit plans, standard health benefit plans, and basic coverage plans. The provisions take effect on January 1, 2026.